Research programme: HBV surface antigen inhibitors - Arbutus Biopharma

Drug Profile

Research programme: HBV surface antigen inhibitors - Arbutus Biopharma

Latest Information Update: 06 Sep 2016

Price : $50

At a glance

  • Originator Enantigen Therapeutics
  • Developer Arbutus Biopharma
  • Class Antivirals; Small molecules
  • Mechanism of Action Surface antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hepatitis B

Most Recent Events

  • 30 Aug 2016 Arbutus terminates its licence for VLP technology with Kuros
  • 03 Aug 2015 Tekmira Pharmaceuticals is now called Arbutus Biopharma
  • 20 Jul 2015 Arbutus Biopharma intends to file an IND application with the US FDA in USA for Hepatitis B
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top